Overviews of all the SERM breast cancer prevention trial using tamoxifen, raloxifene, lasofoxifene, or arzoxifene. Recent overview provides clear evidence for extended benefits and minimal side effects in the five years following active treatment with these agents.
Recent work also involves review of the use of aromatase inhibitors for adjuvant treatment with plans to also look at them in prevention.
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet, May 25;381(9880):1827-34.
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings Steve, DeCensi A, Dowsett M, et al for the SERM Chemoprevention of Breast Cancer Overview Group (2013).
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol., 28(3):509-18.
Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010).
Overview of the main outcomes in breast cancer prevention trials. Lancet, 361:296-300.
Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S and Boyle P (2003).